Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

8304	Companies
115199	Keywords
55516	Articles
62566	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 04/18/2024 at 07:00, 7 months 4 days ago

Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity
Biophytis forms new Scientific Advisory Board for phase 2 OBA clinical study in obesity, including Professor Dennis Villareal and Professor Francisco Guarner. IND filing with FDA imminent

Biophytis Scientific Advisory Board Obesity Phase 2 OBA Clinical Study IND Filing
BRIEF

published on 04/15/2024 at 07:05, 7 months 7 days ago

Biophytis Enhances Intellectual Property in Obesity Treatment with New Patent Application

Biophytis Pharmaceuticals Patent Application BIO101 Obesity
REGULATED PRESS RELEASE

published on 04/15/2024 at 07:00, 7 months 7 days ago

Biophytis files a patent application and strengthens its intellectual property in obesity
Biophytis files a patent application to strengthen its intellectual property in obesity. The new patent extends BIO101's exclusivity period in treating obesity, positioning Biophytis in a fast-growing market

Biophytis Intellectual Property Clinical Trial Patent Application Obesity
BRIEF

published on 04/08/2024 at 23:17, 7 months 13 days ago

Biophytis Reports 2023 Financial Results and Business Updates

Biophytis Financial Results 2023 Sarcopenia BIO101 COVID-19 Treatment
BRIEF

published on 04/08/2024 at 23:15, 7 months 13 days ago

Biophytis Initiates Phase 2 Clinical Study for Obesity Treatment with BIO101

Biophytis Obesity Treatment BIO101 GLP-1 Receptor Agonists OBA Phase 2 Study
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:12, 7 months 13 days ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results and business update, highlighting progress in clinical programs and partnerships. CEO Stanislas Veillet shares insights on growth strategies and collaborations

Financial Results Biophytis Partnerships Clinical Programs Growth Strategies
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:10, 7 months 13 days ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis launches OBA Phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone), aiming to address muscle loss from obesity treatment and promising results in preclinical studies. Clinical study expected to start mid-2024 with results in 2025

Biophytis Clinical Study BIO101 OBA Phase 2 Obesity
BRIEF

published on 04/08/2024 at 23:09, 7 months 13 days ago

Biophytis announces its 2023 financial results and provides an update on its activities

Biophytis Funding Clinical Development 2023 Financial Results BIO101
BRIEF

published on 04/08/2024 at 23:05, 7 months 13 days ago

Biophytis Announces Phase 2 Clinical Study in Obesity Treatment with BIO101

Biophytis Obesity Treatment BIO101 OBA Phase 2 Clinical Study GLP-1 Receptor Agonists
PRESS RELEASE

published on 04/08/2024 at 23:04, 7 months 13 days ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & updates business activities. Successfully developing clinical programmes & obtaining FDA approval for SARA-31 trial in sarcopenia

Biophytis FDA Approval 2023 Financial Results Clinical Programmes SARA-31 Trial

Accesswire

Published on 11/22/2024 at 09:00, 2 hours 15 minutes ago

Industrial Software Company mlean Celebrates 10 Years of Continuous Improvement
Published on 11/22/2024 at 00:00, 11 hours 15 minutes ago

Gratomic Announces Company and Operational Update
Published on 11/21/2024 at 22:05, 13 hours 10 minutes ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 13 hours 25 minutes ago

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 15 hours ago

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals

View all ACCESSWIRE

EQS Group

Published on 11/22/2024 at 11:06, 9 minutes ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
Published on 11/22/2024 at 11:00, 15 minutes ago

Holding(s) in Company
Published on 11/22/2024 at 10:46, 29 minutes ago

Original-Research: ad pepper media International N.V. (von First Berlin Equity Research GmbH): Buy
Published on 11/22/2024 at 09:45, 1 hour 30 minutes ago

The GSMA – China Unicom Open Gateway Global Use Case Innovation Challenge has begun!
Published on 11/22/2024 at 09:23, 1 hour 52 minutes ago

Turkiye Garanti Bankasi A.S.: Announcement regarding issuance of subordinated notes

Les Echos

Published on 11/21/2024 at 06:58, 1 day 4 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 15 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 17 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 17 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 2 days 3 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE